Feedback
Settings

Settings

Goto Application

1,872 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(RVCNQQGZJWVLIP-VPCXQMTMSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 188
1.WO/2025/255168MODIFIED CAS12 GUIDES AND USES THEREOF
WO - 11.12.2025
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
 Appl.No PCT/US2025/032145 Applicant PIONEER HI-BRED INTERNATIONAL, INC. Inventor MAY, Andrew Paul
Disclosed herein are compositions, kits methods related to improved Cas12 systems, specifically including Cas12 guide RNAs. In particular, the present disclosure provides insights and technologies relating to Cas12f systems.
2.1020250166362RNA 간섭을 위한 이중 가닥 올리고뉴클레오티드 조성물 및 이와 관련된 방법
KR - 27.11.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No 1020257030816 Applicant 웨이브 라이프 사이언시스 리미티드 Inventor 바기즈 챈드라
본 개시는 이중 가닥 올리고뉴클레오티드, 조성물 및 이와 관련된 방법을 제공한다. 본 개시는 염기 서열, 화학적 변형(예: 당, 염기 및/또는 뉴클레오티드 간 결합의 변형) 또는 이의 패턴 및/또는 입체화학(예: 백본 키랄 중심(키랄 뉴클레오티드간 결합)의 입체화학) 및/또는 이의 패턴과 같은 이중 가닥 올리고뉴클레오티드의 구조적 요소가 올리고뉴클레오티드 특성 및 활성, 예를 들어 RNA 간섭(RNAi) 활성, Ago2 로딩, 열 안정성, 생체 내 안정성, 조직 및 세포로의 전달 등에 상당한 영향을 미칠 수 있다는 인식을 포함한다. 본 공개는 또한 제공된 이중 가닥 올리고뉴클레오티드 조성물을 사용하여 예를 들어 RNA 간섭에서 간 질환, 중추 신경계(CNS) 질환 등의 질병을 치료하는 방법을 제공한다.
3.1020250166303폴리(A)를 포함하는 폴리뉴클레오타이드 분자 및 이의 용도
KR - 27.11.2025
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
 Appl.No 1020257036108 Applicant 센젠 센신 바이오테크놀로지 컴퍼니 리미티드 Inventor 황, 후이
적어도 30개의 뉴클레오타이드를 갖는 변형된 폴리(A)를 포함하는 폴리뉴클레오타이드가 제공된다. 변형된 폴리(A)는 i) A 뉴클레오타이드로 이루어진 폴리뉴클레오타이드로서 정의되는 적어도 2개의 R 요소; 및 ii) 적어도 하나의 S 요소를 포함한다. S 요소는 a) A 뉴클레오타이드 이외의 뉴클레오타이드이거나, b) 적어도 2개의 뉴클레오타이드로 이루어지며, 양쪽 단부의 뉴클레오타이드는 A 뉴클레오타이드가 아니다. S 요소의 총 수는 R 요소의 총 수보다 1개 더 적고, S 요소는 R 요소에 연결되고, S 요소 각각은 R 요소에 의해 플랭킹된다. 본 발명은 또한, 폴리뉴클레오타이드를 포함하는 벡터 및 숙주 세포, RNA를 제조하기 위해 폴리뉴클레오타이드를 사용하는 방법 및 이로부터 제조되는 RNA, 폴리뉴클레오타이드, RNA, 벡터, 및/또는 숙주 세포를 포함하는 약학적 조성물 또는 LNP, 및 이의 용도에 관한 것이다.
4.1020250162839AAVS1 세이프 하버 부위에서의 녹인 전략
KR - 19.11.2025
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
 Appl.No 1020257034274 Applicant 에멘도바이오 인코포레이티드 Inventor 엠마누엘 라피
서열번호 1-24195 중 어느 하나에 제시된 서열의 17-50개의 연속 뉴클레오티드를 갖는 가이드 서열 부분을 포함하는 RNA 분자 및 이의 조성물, 방법 및 용도.
5.20250346908FLUOROGENIC NUCLEOSIDES
US - 13.11.2025
Int.Class C12N 15/115
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
 Appl.No 18869037 Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE Inventor Jonathan Rittichier

Provided herein are Anorogenic nucleosides (e.g., Anorogenic nucleoside triphosphates (NTPs), e.g., Anorogenic reversible terminator nucleoside triphosphates) which can be used in the synthesis of Anorogenic oligonucleotides (e.g., Anorogenic DNA or RNA oligonucleotides, such as Anorogenic RNA aptamers). The Anorogenic oligonucleotides (e.g., Anorogenic DNA or RNA oligonucleotides, such as, Anorogenic RNA aptamers) can be used as Anorogenic probes to detect targets (e.g., antigens, biomarkers).

6.WO/2025/228326RECOMBINANT RNA MOLECULE AND USE THEREOF
WO - 06.11.2025
Int.Class C12N 15/63
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
 Appl.No PCT/CN2025/091753 Applicant SHENZHEN SHENXIN BIOTECHNOLOGY CO., LTD. Inventor LI, Linxian
Provided are a recombinant RNA molecule and a use thereof. The recombinant RNA molecule comprises a polynucleotide encoding a polypeptide of interest and 5'-UTR and/or 3'-UTR. The recombinant RNA molecule has improved translation efficiency and/or stability; and the expression level of the polypeptide and/or protein is increased. Also provided are a vector encoding the recombinant RNA molecule, a pharmaceutical composition comprising the recombinant RNA molecule, and a method for treating or preventing a disease by using the recombinant RNA molecule.
7.WO/2025/228409LIPID NANOPARTICLE AND USE THEREOF
WO - 06.11.2025
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No PCT/CN2025/092313 Applicant SHENZHEN SHENXIN BIOTECHNOLOGY CO., LTD. Inventor LI, Linxian
Provided is a lipid nanoparticle, which comprises an active component, an ionizable lipid, an auxiliary lipid, a structural lipid, and a polymer lipid. The polymer lipid accounts for 0-0.8 mol% of the total lipid existing in the lipid nanoparticle. The reduction in the content of the polymer lipid in the lipid nanoparticle can change the delivery specificity of the lipid nanoparticle, such that the lipid nanoparticle can target the spleen or immune cells.
8.120898004用于预测和/或监测心血管疾病及其干预的方法和组合物
CN - 04.11.2025
Int.Class C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
 Appl.No 202480021199.8 Applicant 心脏诊断公司 Inventor M·V·多甘
本文档描述了用于预测心血管疾病（CVD）的方法和组合物。具体地，本文档描述了用于确定至少一个CpG基因座的甲基化状态和至少一个单核苷酸多态性（SNP）的序列的方法和组合物，所述甲基化状态和所述序列可预测CVD的检测或从CVD中存活的估计。
9.120884604寡核苷酸组合物及其使用方法
CN - 04.11.2025
Int.Class A61K 31/712
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
 Appl.No 202510680630.6 Applicant 波涛生命科学有限公司 Inventor C·瓦格斯
本公开尤其提供了设计的寡核苷酸、组合物及其方法。在一些实施方案中，所提供的寡核苷酸组合物提供了改善的单链RNA干扰和/或RNA酶H介导的敲低。本公开尤其涵盖以下认识：寡核苷酸的结构元件，诸如碱基序列、化学修饰(例如，糖、碱基和/或核苷酸间键联的修饰)或其样式、与附加的化学部分的缀合和/或立体化学[例如，主链手性中心的立体化学(手性核苷酸间键联)]和/或其样式，可对寡核苷酸的性质和活性例如RNA干扰(RNAi)活性、稳定性、递送等具有显著影响。在一些实施方案中，本公开提供了使用所提供的寡核苷酸组合物(例如在RNA干扰和/或RNA酶H介导的敲低中)治疗疾病的方法。
10.120858173用KP34聚合酶制造信使RNA
CN - 28.10.2025
Int.Class C12N 9/12
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
10Transferases (2.)
12transferring phosphorus containing groups, e.g. kinases (2.7)
 Appl.No 202480017490.8 Applicant 赛诺菲巴斯德有限公司 Inventor 崔建平
本披露提供了用于使用克雷伯氏菌属噬菌体KP34RNA聚合酶改善信使RNA的体外转录(IVT)的方法和组合物。特别地，本披露提供了一种用于制造信使RNA的方法，该方法包括：(a)提供包含编码用于表达多肽或蛋白质的mRNA转录物的核酸序列的DNA模板；(b)在适合于该mRNA转录物的IVT的条件下，使该DNA模板与克雷伯氏菌属噬菌体KP34RNA聚合酶接触。
# -